12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nurelin amantadine: Final Phase II/III data

Final data from the double-blind, U.S. Phase II/III EASED trial in 83 patients with PD showed that once-daily 340 and 420 mg doses of oral ADS-5102 each met the primary endpoint of improving levodopa-induced dyskinesia as measured by the mean change in UDysRS total score from baseline to week 8 vs. placebo (placebo-adjusted improvements of 11.3 and 10 points, respectively, p=0.005 and p=0.013). The once-daily 260 mg dose of ADS-5102 led to a non-significant placebo-adjusted improvement of 5.6 points on...

Read the full 377 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >